Want to join the conversation?
$PFE's research and development expenses for 2015 slid by 8% from last year. This decline was primarily due to non-recurrence of a charge associated with a collaborative arrangement with Merck, lower clinical trial expenses for various studies, lower upfront payments, and the favorable impact of foreign exchange of 2%.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.
Well this is big! I don’t know if it’s someone’s monopoly or genuine excitement, but either way, $CSX is up 23% after market closed. I heard some activist investor is going to blow big money into CSX Corp. Anyone mind explaining?